SCIENTIFIC AGENDA

Session I: Selected abstracts
Chairs: Mario Dicato, MD and Eric Van Cutsem, MD, PhD

Preliminary results of the Polish clinical trial on extended D2 (D2+) vs. standard D2 lymphadenectomy in gastric cancer patients
Piotr Kolodziejczyk, et al.

Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Iterim analysis of a randomized German AIO phase II study
Markus Moehler, et al.

Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results
Yoon-Koo Kang, et al.

UGT1A1 promoter polymorphisms and pharmacodynamic/pharmacokinetic relationship in advanced colorectal cancer treated with FOLFIRI regimen
Guiseppe Toffoli, et al.

Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): A comparative analysis of N9741 and AVF2107
Axel Grothey, et al.

Bevacizumab plus IFL improves outcomes of patients with metastatic colorectal cancer independent of baseline risk
Herbert Hurwitz, et al.